Vertex Pharmaceuticals
NEWS
Now that July is over, the U.S. Food and Drug Administration (FDA) appears to be back in full swing with a full docket of drug decisions to make. There are four therapeutics with PDUFA dates this week involving six biopharma companies. Here’s a look.
Shares of Galapagos NV fell more than 15 percent Thursday afternoon and continued to fall in premarket trading after the Belgium-based company said AbbVie opted to walk away from its cystic fibrosis collaboration.
An experimental triple combination treatment for cystic fibrosis has landed Vertex Pharmaceuticals at the top of EvaluatePharma’s “World Preview 2018” list.
Vertex Pharmaceuticals has substantially expanded the San Diego-based research and development facility.
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
Shares of CRISPR Therapeutics plunged dramatically Wednesday after the U.S. Food and Drug Administration placed a clinical hold on a planned sickle cell disease treatment the company was in the process of developing with Vertex Pharmaceuticals.
EIP Pharma, based in Cambridge, Massachusetts, closed on a $20.5 million Series B financing. The round was led by Access Industries.
AstraZeneca and its biologics research-and-development arm, MedImmune, indicated that its Fasenra (benralizumab) did not meet its primary endpoint in patients with moderate to very severe COPD.
The Wilmington, Massachusetts-based contract research organization (CRO) Charles River Laboratories International extended its current collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
JOBS
IN THE PRESS